Extract from the Register of European Patents

EP About this file: EP2051710

EP2051710 - COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.09.2012
Database last updated on 08.04.2026
Most recent event   Tooltip07.09.2012No opposition filed within time limitpublished on 10.10.2012  [2012/41]
Applicant(s)For all designated states
Bausch & Lomb Incorporated
One Bausch & Lomb Place
Rochester, NY 14604-2701 / US
[2009/18]
Inventor(s)01 / KERPPOLA, Raili
820 Heatherway
Ann Arbor, MI 48104 / US
02 / PHILLIPS, Gary
137 Tennyson Way
Pittsford, NY 14534 / US
03 / HU, Zhenze
28 Wenham Lane
Pittsford, New-York 14534 / US
04 / WARD, Keith Wayne
5340 Lincoln Road
Ontario, NY 14519 / US
 [2011/44]
Former [2009/18]01 / KERPPOLA, Raili
820 Heatherway
Ann Arbor, MI 48104 / US
02 / PHILLIPS, Gary
137 Tennyson Way
Pittsford, NY 14534 / US
03 / HU, Zhenze
35, Broadmoor Trail
Fairport, NY 14450 / US
04 / WARD, Keith Wayne
5340 Lincoln Road
Ontario, NY 14519 / US
Representative(s)Glas, Holger, et al
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2009/18]Glas, Holger, et al
Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3
80335 München / DE
Application number, filing date07813637.101.08.2007
[2009/18]
WO2007US74943
Priority number, dateUS20060836078P07.08.2006         Original published format: US 836078 P
[2009/18]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008021729
Date:21.02.2008
Language:EN
[2008/08]
Type: A2 Application without search report 
No.:EP2051710
Date:29.04.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 21.02.2008 takes the place of the publication of the European patent application.
[2009/18]
Type: B1 Patent specification 
No.:EP2051710
Date:02.11.2011
Language:EN
[2011/44]
Search report(s)International search report - published on:EP09.10.2008
ClassificationIPC:A61K31/343, A61K31/404, A61K31/4184, A61K31/4439, A61K31/4709, A61K31/4725, A61K45/06, A61K39/395, A61P29/02, A61P29/00
[2011/44]
CPC:
A61K31/4725 (EP,KR,US); A61K39/3955 (EP,KR,US); A61K31/343 (EP,KR,US);
A61K31/404 (EP,KR,US); A61K31/4184 (EP,KR,US); A61K31/4439 (EP,KR,US);
A61K31/4709 (EP,KR,US); A61K45/06 (EP,KR,US); A61P27/00 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P29/02 (EP);
A61P43/00 (EP); A61P9/10 (EP) (-)
C-Set:
A61K31/343, A61K2300/00 (US,EP);
A61K31/404, A61K2300/00 (US,EP);
A61K31/4184, A61K2300/00 (US,EP);
A61K31/4439, A61K2300/00 (US,EP);
A61K31/4709, A61K2300/00 (EP,US);
A61K31/4725, A61K2300/00 (EP,US);
A61K39/3955, A61K2300/00 (EP,US)
(-)
Former IPC [2009/18]A61K31/343, A61K31/404, A61K31/4184, A61K31/4439, A61K31/4709, A61K31/4725, A61K31/395, A61K45/06, A61P27/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/18]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG, VERMINDERUNG, VERBESSERUNG ODER LINDERUNG VON ERKRANKUNGEN DES HINTEREN AUGENSEGMENTS[2009/18]
English:COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES[2009/18]
French:COMPOSITIONS ET PROCÉDÉS POUR TRAITER, RÉDUIRE, AMÉLIORER OU SOULAGER DES MALADIES OPHTALMIQUES DU SEGMENT POSTÉRIEUR[2009/18]
Entry into regional phase06.02.2009National basic fee paid 
06.02.2009Designation fee(s) paid 
06.02.2009Examination fee paid 
Examination procedure19.05.2008Request for preliminary examination filed
International Preliminary Examining Authority: EP
06.02.2009Amendment by applicant (claims and/or description)
06.02.2009Examination requested  [2009/18]
25.05.2009Despatch of a communication from the examining division (Time limit: M04)
01.10.2009Reply to a communication from the examining division
12.05.2010Despatch of a communication from the examining division (Time limit: M04)
13.09.2010Reply to a communication from the examining division
14.04.2011Communication of intention to grant the patent
11.08.2011Fee for grant paid
11.08.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.05.2009
Opposition(s)03.08.2012No opposition filed within time limit [2012/41]
Fees paidRenewal fee
07.08.2009Renewal fee patent year 03
06.08.2010Renewal fee patent year 04
08.08.2011Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]   MICHEL SHAWKAT SHAFIK ET AL: "Multifocal choroiditis and panuveitis: immunomodulatory therapy.", OPHTHALMOLOGY FEB 2002, vol. 109, no. 2, February 2002 (2002-02-01), pages 378 - 383, XP002483909, ISSN: 0161-6420 [Y] 16,33,34,36-38,44,55 * page 378, column R, paragraph 4 - page 379, column R, paragraph 1 * * page 380, column L, paragraph 1 - page 381, column R, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/S0161-6420(01)00901-0
 [Y]   JAMPOL L M ET AL: "Treatment of juxtafoveal and extrafoveal choroidal neovascularization in the era of photodynamic therapy with verteporfin", AMERICAN JOURNAL OF OPHTHALMOLOGY 2002 US, vol. 134, no. 1, 2002, pages 99 - 101, XP002483910, ISSN: 0002-9394 [Y] 71-73 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0002-9394(02)01463-0
 [Y]   TENNANT M T ET AL: "Photodynamic Therapy (PDT) in Multifocal Choroiditis (MFC).", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2002, 2002, & ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FORT LAUDERDALE, FLORIDA, USA; MAY 05-10, 2002, pages Abstract No. 595, XP008092817 [Y] 71-73 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.